Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Editorial
|
Volume 16, Issue 14
|
pp. 11122–11124
Targeted cancer therapy: the initial high concentration may slow down the selection for resistance
Back to article
Figure 2
(2 of 2)
−
100%
+
Figure 2.
One of my targeted combinations.
Capmatinib – standard everyday use. All other medications - reverse dose application -are given on day 1 only. The number of tablets on day1 are shown.
